AKAO Achaogen Inc.

1.23
-0.06  -5%
Previous Close 1.29
Open 1.3
Price To Book 2.28
Market Cap 56226387
Shares 45,712,510
Volume 1,129,211
Short Ratio
Av. Daily Volume 1,214,902

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial delayed due to decision to run a further Phase 1 trial first - noted May 4, 2018.
C-Scape
Complicated urinary tract infections (cUTI) due to multi-drug resistant (MDR) pathogens
FDA approval for cUTI but CRL received for the treatment of bloodstream infection (BSI).
Plazomicin
Complicated urinary tract infections (cUTI)
Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
Plazomicin - CARE
Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE)

Latest News

  1. Could Achaogen, Inc.’s (NASDAQ:AKAO) Investor Composition Influence The Stock Price?
  2. Today's Research Reports on Trending Tickers: Achaogen and Arcadia Biosciences
  3. Recent Analysis Shows Best Buy Co., News Corporation, Semtech, Achaogen, Infosys, and Galapagos NV Market Influences — Renewed Outlook, Key Drivers of Growth
  4. Edited Transcript of AKAO earnings conference call or presentation 8-Nov-18 1:30pm GMT
  5. Health Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics
  6. Achaogen Announces Multiple Plazomicin Presentations at the American Society of Health Systems Pharmacists (ASHP) Midyear Clinical Meeting
  7. Achaogen Announces Presentations at Two Investor Healthcare Conferences in November
  8. Achaogen (AKAO) Reports Q3 Loss, Misses Revenue Estimates
  9. Achaogen: 3Q Earnings Snapshot
  10. Achaogen Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  11. 4 months after drug approval, Achaogen eyes fire sale
  12. Achaogen Announces Review of Strategic Alternatives and Corporate Restructuring
  13. Achaogen to Host Conference Call and Webcast of Third Quarter 2018 Financial Results on November 8, 2018
  14. Consolidated Research: 2018 Summary Expectations for Insys Therapeutics, Achaogen, Astec Industries, Central European Media Enterprises, Pzena Investment Management, and Clementia Pharmaceuticals — Fundamental Analysis, Key Performance Indications

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19520837
  2. 8-K - Current report 19507186
  3. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 181231592
  4. CT ORDER - Confidential treatment order 181202608
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170641
  6. 8-K - Current report 181168274
  7. 8-K - Current report 181157796
  8. 8-K - Current report 181125739
  9. 8-K/A [Amend] - Current report 181073892
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18995572